Аналитика NYSE на 20 ноября
/uploads/images/
Спайдер незначительно повышается перед открытием торгов на NYSE.
Европейские индексы на отрицательной территории.
SPY (внутридневной график) боковое движение на премаркете премаркете. Поддержка 178.80, сопротивление 179.80
Премаркет NYSE/NASDAQ:
Повышаются на премаркете:
• In reaction to strong earnings/guidance: STV +9.2%, LZB +8.5% (also increased its quarterly dividend by 50% to $0.06 per share), JCP +5.4%, DE +3.7%, ADT +0.9%, (also enters into accelerated share repurchase agreement to repurchase ~400 mln of common stock).
• M&A news: TEVA +1.6% (Bloomberg discusses merger possibility between Teva and Mylan or VRX, according to reports; upgraded to Positive from Neutral at Susquehanna).
• Select oil/gas related names showing strength: SD +4.5%, RDS.A +0.8%, BP +0.7%.
• Select solar names showing strength: RSOL +10.8%, SPWR +4.3%, JKS +3.4%, TSL +3%, YGE +2.2%, SOL +1.6%.
• Other news: IPCI +21.2% (continued strength), HNR +19.5% (announces revised $400 mln proposal from Pluspetrol for co's interest in Venezuela; termination of negotiations with Vitol), UNIS +17.9% (attributed to reports of deal with Hikma), BMRN +4.9% (confirms FDA Advisory Commitee recommends approval for Vimizim for the treatment of patients with Morquio A syndrome), MDR +4.4% (ticking higher, subsidiaries was awarded project for a customer in the Arabian Gulf. The value is approximately US$ 200 million and will be included in McDermott's fourth quarter 2013 backlog), VEEV +4.3% ( following positive Mad Money mention), OMER +4.1% (announces FDA acceptance of Omidria as proprietary name for OMS302), OTIV +3.3% (Silk & Sons disclosed stake), YHOO +3.1% (increases share buyback authorization by $5 bln), NQ +2.9% (following conference yesterday), NOK +2.6% and ALU +1.3% (still checking), RYAAY +2.3% / ZNH +1.1% (still checking), ARO +2% ( Hirzel Capital disclosed stake), BSX +1.2% (receives FDA clearance and CE Mark approval for Direxion Torqueable Microcatheter), SSYS +1.2% (continued momentum), HLF +0.8% (William P. Stiritz, Chairman of Post Foods (POST), disclosed 6.38% active stake in 13D filing; plans to interact with Company management), CRM +0.7% ( following positive Mad Money mention), CAT +0.6% (following DE results), ZNGA +0.5% (picked up in afternoon trade on reports that the co received favorable patent verdict in Texas case), AMGN +0.5% (announces evolocumab (AMG 145) results from first 52-week study of PCSK9 inhibitor to reduce LDL cholesterol; Amgen tgt to $142 from $138 at Deutsche Bank), FNF +0.4% (Dan Loeb's Third Point Capital reported new stakes (as of 9/30) in FNF (2.1 mln shares) and NLSN (1.0 mln) in an amended 13F filing out last night after the close).
• Analyst comments: COG +2.1% (upgraded to Outperform from Market Perform at Bernstein ), PCLN +1.8% (added to Conviction Buy list at Goldman), BBY +1.6% (upgraded to Buy from Neutral at Citigroup), PSO +1.4% (ticking higher, upgraded to Buy from Neutral at BofA), GMCR +1.3% ( initiated with a Buy at Buckingham Research).
Снижаются на премаркете:
• In reaction to disappointing earnings/guidance: CHLN -15.8%, QUNR -5.8%, GFI -4.2%, LOW -3.8%, MODN -3%.
• Select metals/mining stocks trading lower: IAG -2.3%, GG -1.2%, AG -1.1%, ABX -1%, GLD -0.8%, EGO -0.8%, HL -0.8%.
• Other news: AEZS -8.2% (announces proposed public offering of common shares and warrants), CRNT -6.9% (announces proposed public offering of common stock, size not disclosed), LOV -6.5% (announced that Great Hill Partners, LLC and its affiliates, as selling stockholders, intend to sell shares of common stock of Spark Networks), SSW -5.7% ( plans to offer 3.5 mln Class A common shares in a registered public offering ), ICLD -5.3% (modestly pulling back), FU -4.8% (lower despite reiterating denial of allegations), GOOD -4% (plans to sell shares of its common stock in an underwritten public offering), NHI -1.8% (announces offering of 4.5 million shares of common stock; to acquire 25 independent living facilities), TEF -1.3% (still checking), BUD -1.1% (still checking), GPK -0.9% (announces commencement of secondary common stock offering of ~47.87 mln shares by selling stockholders; announces $200 mln stock repurchase), CLVS -0.6% (acquires Ethical Oncology Science to gain rights to lucitanib, a unique dual-selective Phase 2 FGFR/VEGFR inhibitor, files for 3,713,731 share common stock offering by selling shareholders).
• Analyst comments: TWTR -2% (downgraded to Hold from Buy at Cantor), CHRW -1.6% (downgraded to Hold from Buy at Deutsche Bank), WDAY -1.4% (downgraded to Market Perform from Outperform at Cowen), TSLA -1.3% (Hearing tgt cut to $120 from $141 at Barclays), PDCO -0.7% (Patterson Companies downgraded to Neutral from Buy at UBS), BA -0.7% (downgraded to Perform from Outperform at Oppenheimer), MOS -0.6% ( downgraded to Hold from Buy at BGC Partners), POT -0.6% (downgraded to Hold from Buy at BGC Partners)
Интересные новостные акции NYSE и NASDAQ:
DE – шорт ниже 85.00
LZB – лонг выше максимума премаркета
LOW – лонг выше максимума премаркета
Shark Traders предлагает пройти всем своим трейдерам абсолютно бесплатное обучение трейдингу на NYSE. От вас потребуется только торговый счет и желание развиваться. Вы еще не являетесь нашим клиентом — не проблема! Вы можете пройти наше обучение за символическую плату: всего 4500 рублей.
Что включает в себя бесплатное обучение трейдингу:
Видеокурс
Доступ к профессиональным макроэкономическим и корпоративным новостям NYSE
Доступ к закрытым вебинарам
Доступ к записям новых лекций
Каждый месяц количество уроков увеличивается! Если вы приобретаете доступ к обучающему порталу или являетесь нашим клиентом, то вы получаете абсолютно все новые видеоролики и возможность участвовать в наших закрытых вебинарах.
Какой же новостной трейдинг без хорошей новостной ленты? Мы заботимся и помогаем тем, кто работает с нами, поэтому в личном кабинете помимо доступа к обучающим видео и вебинарам вы сможете прочитать все самые свежие и актуальные макроэкономические и корпоративные новости NYSE в реальном времени абсолютно бесплатно. Мы зарабатываем, когда зарабатываете вы!
Полная информация о бесплатном обучающем курсе
Европейские индексы на отрицательной территории.
SPY (внутридневной график) боковое движение на премаркете премаркете. Поддержка 178.80, сопротивление 179.80
Премаркет NYSE/NASDAQ:
Повышаются на премаркете:
• In reaction to strong earnings/guidance: STV +9.2%, LZB +8.5% (also increased its quarterly dividend by 50% to $0.06 per share), JCP +5.4%, DE +3.7%, ADT +0.9%, (also enters into accelerated share repurchase agreement to repurchase ~400 mln of common stock).
• M&A news: TEVA +1.6% (Bloomberg discusses merger possibility between Teva and Mylan or VRX, according to reports; upgraded to Positive from Neutral at Susquehanna).
• Select oil/gas related names showing strength: SD +4.5%, RDS.A +0.8%, BP +0.7%.
• Select solar names showing strength: RSOL +10.8%, SPWR +4.3%, JKS +3.4%, TSL +3%, YGE +2.2%, SOL +1.6%.
• Other news: IPCI +21.2% (continued strength), HNR +19.5% (announces revised $400 mln proposal from Pluspetrol for co's interest in Venezuela; termination of negotiations with Vitol), UNIS +17.9% (attributed to reports of deal with Hikma), BMRN +4.9% (confirms FDA Advisory Commitee recommends approval for Vimizim for the treatment of patients with Morquio A syndrome), MDR +4.4% (ticking higher, subsidiaries was awarded project for a customer in the Arabian Gulf. The value is approximately US$ 200 million and will be included in McDermott's fourth quarter 2013 backlog), VEEV +4.3% ( following positive Mad Money mention), OMER +4.1% (announces FDA acceptance of Omidria as proprietary name for OMS302), OTIV +3.3% (Silk & Sons disclosed stake), YHOO +3.1% (increases share buyback authorization by $5 bln), NQ +2.9% (following conference yesterday), NOK +2.6% and ALU +1.3% (still checking), RYAAY +2.3% / ZNH +1.1% (still checking), ARO +2% ( Hirzel Capital disclosed stake), BSX +1.2% (receives FDA clearance and CE Mark approval for Direxion Torqueable Microcatheter), SSYS +1.2% (continued momentum), HLF +0.8% (William P. Stiritz, Chairman of Post Foods (POST), disclosed 6.38% active stake in 13D filing; plans to interact with Company management), CRM +0.7% ( following positive Mad Money mention), CAT +0.6% (following DE results), ZNGA +0.5% (picked up in afternoon trade on reports that the co received favorable patent verdict in Texas case), AMGN +0.5% (announces evolocumab (AMG 145) results from first 52-week study of PCSK9 inhibitor to reduce LDL cholesterol; Amgen tgt to $142 from $138 at Deutsche Bank), FNF +0.4% (Dan Loeb's Third Point Capital reported new stakes (as of 9/30) in FNF (2.1 mln shares) and NLSN (1.0 mln) in an amended 13F filing out last night after the close).
• Analyst comments: COG +2.1% (upgraded to Outperform from Market Perform at Bernstein ), PCLN +1.8% (added to Conviction Buy list at Goldman), BBY +1.6% (upgraded to Buy from Neutral at Citigroup), PSO +1.4% (ticking higher, upgraded to Buy from Neutral at BofA), GMCR +1.3% ( initiated with a Buy at Buckingham Research).
Снижаются на премаркете:
• In reaction to disappointing earnings/guidance: CHLN -15.8%, QUNR -5.8%, GFI -4.2%, LOW -3.8%, MODN -3%.
• Select metals/mining stocks trading lower: IAG -2.3%, GG -1.2%, AG -1.1%, ABX -1%, GLD -0.8%, EGO -0.8%, HL -0.8%.
• Other news: AEZS -8.2% (announces proposed public offering of common shares and warrants), CRNT -6.9% (announces proposed public offering of common stock, size not disclosed), LOV -6.5% (announced that Great Hill Partners, LLC and its affiliates, as selling stockholders, intend to sell shares of common stock of Spark Networks), SSW -5.7% ( plans to offer 3.5 mln Class A common shares in a registered public offering ), ICLD -5.3% (modestly pulling back), FU -4.8% (lower despite reiterating denial of allegations), GOOD -4% (plans to sell shares of its common stock in an underwritten public offering), NHI -1.8% (announces offering of 4.5 million shares of common stock; to acquire 25 independent living facilities), TEF -1.3% (still checking), BUD -1.1% (still checking), GPK -0.9% (announces commencement of secondary common stock offering of ~47.87 mln shares by selling stockholders; announces $200 mln stock repurchase), CLVS -0.6% (acquires Ethical Oncology Science to gain rights to lucitanib, a unique dual-selective Phase 2 FGFR/VEGFR inhibitor, files for 3,713,731 share common stock offering by selling shareholders).
• Analyst comments: TWTR -2% (downgraded to Hold from Buy at Cantor), CHRW -1.6% (downgraded to Hold from Buy at Deutsche Bank), WDAY -1.4% (downgraded to Market Perform from Outperform at Cowen), TSLA -1.3% (Hearing tgt cut to $120 from $141 at Barclays), PDCO -0.7% (Patterson Companies downgraded to Neutral from Buy at UBS), BA -0.7% (downgraded to Perform from Outperform at Oppenheimer), MOS -0.6% ( downgraded to Hold from Buy at BGC Partners), POT -0.6% (downgraded to Hold from Buy at BGC Partners)
Интересные новостные акции NYSE и NASDAQ:
DE – шорт ниже 85.00
LZB – лонг выше максимума премаркета
LOW – лонг выше максимума премаркета
Shark Traders предлагает пройти всем своим трейдерам абсолютно бесплатное обучение трейдингу на NYSE. От вас потребуется только торговый счет и желание развиваться. Вы еще не являетесь нашим клиентом — не проблема! Вы можете пройти наше обучение за символическую плату: всего 4500 рублей.
Что включает в себя бесплатное обучение трейдингу:
Видеокурс
Доступ к профессиональным макроэкономическим и корпоративным новостям NYSE
Доступ к закрытым вебинарам
Доступ к записям новых лекций
Каждый месяц количество уроков увеличивается! Если вы приобретаете доступ к обучающему порталу или являетесь нашим клиентом, то вы получаете абсолютно все новые видеоролики и возможность участвовать в наших закрытых вебинарах.
Какой же новостной трейдинг без хорошей новостной ленты? Мы заботимся и помогаем тем, кто работает с нами, поэтому в личном кабинете помимо доступа к обучающим видео и вебинарам вы сможете прочитать все самые свежие и актуальные макроэкономические и корпоративные новости NYSE в реальном времени абсолютно бесплатно. Мы зарабатываем, когда зарабатываете вы!
Полная информация о бесплатном обучающем курсе
Код для вставки в блог
20 ноября 2013, 18:00
Европейские индексы на отрицательной территории.
SPY (внутридневной график) боковое движение на премаркете премаркете. Поддержка 178.80, сопротивление 179.80
Премаркет NYSE/NASDAQ:
Повышаются на премаркете:
• In reaction to strong earnings/guidance: STV +9.2%, LZB +8.5% (also increased its quarterly dividend by 50% to $0.06 per share), JCP +5.4%, DE +3.7%, ADT +0.9%, (also enters into accelerated share repurchase agreement to repurchase ~400 mln of common stock).
• M&A news: TEVA +1.6% (Bloomberg discusses merger possibility between Teva and Mylan or VRX, according to reports; upgraded to Positive from Neutral at Susquehanna).
• Select oil/gas related names showing strength: SD +4.5%, RDS.A +0.8%, BP +0.7%.
• Select solar names showing strength: RSOL +10.8%, SPWR +4.3%, JKS +3.4%, TSL +3%, YGE +2.2%, SOL +1.6%.
• Other news: IPCI +21.2% (continued strength), HNR +19.5% (announces revised $400 mln proposal from Pluspetrol for co's interest in Venezuela; termination of negotiations with Vitol), UNIS +17.9% (attributed to reports of deal with Hikma), BMRN +4.9% (confirms FDA Advisory Commitee recommends approval for Vimizim for the treatment of patients with Morquio A syndrome), MDR +4.4% (ticking higher, subsidiaries was awarded project for a customer in the Arabian Gulf. The value is approximately US$ 200 million and will be included in McDermott's fourth quarter 2013 backlog), VEEV +4.3% ( following positive Mad Money mention), OMER +4.1% (announces FDA acceptance of Omidria as proprietary name for OMS302), OTIV +3.3% (Silk & Sons disclosed stake), YHOO +3.1% (increases share buyback authorization by $5 bln), NQ +2.9% (following conference yesterday), NOK +2.6% and ALU +1.3% (still checking), RYAAY +2.3% / ZNH +1.1% (still checking), ARO +2% ( Hirzel Capital disclosed stake), BSX +1.2% (receives FDA clearance and CE Mark approval for Direxion Torqueable Microcatheter), SSYS +1.2% (continued momentum), HLF +0.8% (William P. Stiritz, Chairman of Post Foods (POST), disclosed 6.38% active stake in 13D filing; plans to interact with Company management), CRM +0.7% ( following positive Mad Money mention), CAT +0.6% (following DE results), ZNGA +0.5% (picked up in afternoon trade on reports that the co received favorable patent verdict in Texas case), AMGN +0.5% (announces evolocumab (AMG 145) results from first 52-week study of PCSK9 inhibitor to reduce LDL cholesterol; Amgen tgt to $142 from $138 at Deutsche Bank), FNF +0.4% (Dan Loeb's Third Point Capital reported new stakes (as of 9/30) in FNF (2.1 mln shares) and NLSN (1.0 mln) in an amended 13F filing out last night after the close).
• Analyst comments: COG +2.1% (upgraded to Outperform from Market Perform at Bernstein ), PCLN +1.8% (added to Conviction Buy list at Goldman), BBY +1.6% (upgraded to Buy from Neutral at Citigroup), PSO +1.4% (ticking higher, upgraded to Buy from Neutral at BofA), GMCR +1.3% ( initiated with a Buy at Buckingham Research).
Снижаются на премаркете:
• In reaction to disappointing earnings/guidance: CHLN -15.8%, QUNR -5.8%, GFI -4.2%, LOW -3.8%, MODN -3%.
• Select metals/mining stocks trading lower: IAG -2.3%, GG -1.2%, AG -1.1%, ABX -1%, GLD -0.8%, EGO -0.8%, HL -0.8%.
• Other news: AEZS -8.2% (announces proposed public offering of common shares and warrants), CRNT -6.9% (announces proposed public offering of common stock, size not disclosed), LOV -6.5% (announced that Great Hill Partners, LLC and its affiliates, as selling stockholders, intend to sell shares of common stock of Spark Networks), SSW -5.7% ( plans to offer 3.5 mln Class A common shares in a registered public offering ), ICLD -5.3% (modestly pulling back), FU -4.8% (lower despite reiterating denial of allegations), GOOD -4% (plans to sell shares of its common stock in an underwritten public offering), NHI -1.8% (announces offering of 4.5 million shares of common stock; to acquire 25 independent living facilities), TEF -1.3% (still checking), BUD -1.1% (still checking), GPK -0.9% (announces commencement of secondary common stock offering of ~47.87 mln shares by selling stockholders; announces $200 mln stock repurchase), CLVS -0.6% (acquires Ethical Oncology Science to gain rights to lucitanib, a unique dual-selective Phase 2 FGFR/VEGFR inhibitor, files for 3,713,731 share common stock offering by selling shareholders).
• Analyst comments: TWTR -2% (downgraded to Hold from Buy at Cantor), CHRW -1.6% (downgraded to Hold from Buy at Deutsche Bank), WDAY -1.4% (downgraded to Market Perform from Outperform at Cowen), TSLA -1.3% (Hearing tgt cut to $120 from $141 at Barclays), PDCO -0.7% (Patterson Companies downgraded to Neutral from Buy at UBS), BA -0.7% (downgraded to Perform from Outperform at Oppenheimer), MOS -0.6% ( downgraded to Hold from Buy at BGC Partners), POT -0.6% (downgraded to Hold from Buy at BGC Partners)
Интересные новостные акции NYSE и NASDAQ:
DE – шорт ниже 85.00
LZB – лонг выше максимума премаркета
LOW – лонг выше максимума премаркета
Shark Traders предлагает пройти всем своим трейдерам абсолютно бесплатное обучение трейдингу на NYSE. От вас потребуется только торговый счет и желание развиваться. Вы еще не являетесь нашим клиентом — не проблема! Вы можете пройти наше обучение за символическую плату: всего 4500 рублей.
Что включает в себя бесплатное обучение трейдингу:
Видеокурс
Доступ к профессиональным макроэкономическим и корпоративным новостям NYSE
Доступ к закрытым вебинарам
Доступ к записям новых лекций
Каждый месяц количество уроков увеличивается! Если вы приобретаете доступ к обучающему порталу или являетесь нашим клиентом, то вы получаете абсолютно все новые видеоролики и возможность участвовать в наших закрытых вебинарах.
Какой же новостной трейдинг без хорошей новостной ленты? Мы заботимся и помогаем тем, кто работает с нами, поэтому в личном кабинете помимо доступа к обучающим видео и вебинарам вы сможете прочитать все самые свежие и актуальные макроэкономические и корпоративные новости NYSE в реальном времени абсолютно бесплатно. Мы зарабатываем, когда зарабатываете вы!
Полная информация о бесплатном обучающем курсе